Bethesda, MD (PRWEB) August 23, 2006
Even although it is the most widespread inherited trigger of mental impairment, Fragile X Syndrome is still widely unknown to the general public. Affecting almost 1 in 3600 males and 1 in 4000 to 6000 females, people with Fragile X generally display significant intellectual disability, which can range from learning disabilities to severe mental retardation and autism. In addition, both males and females with Fragile X exhibit a variety of physical and behavioral characteristics. With genetic study and the launch of the Human Genome Project in 1990, the gene responsible for Fragile X, FMR1, was identified in 1991. Despite this info, currently there is no cure or gene therapy obtainable for Fragile X. Nevertheless, medications to support aggression, anxiety, hyperactivity, and poor attention span are viable treatment alternatives for numerous patients in controlling the effects of Fragile X.
Behavioral characteristics of Fragile X can include autistic behaviors, attention deficit disorders, speech disturbances, hand biting, hand flapping, poor eye contact and unusual responses or hypersensitivity to stimuli. Due to the fact the impact of Fragile X can be extremely varied for each individual, therapy is determined per patient and ought to be carefully tailored to his/her needs. Common medications used to treat seizure disorders and mood instability such as Phenobarbitol and Valproic Acid, attention deficit and hyperactivity such as Ritalin, Adderall and Concerta, and antipsychotics such as Risperidone and Olanzepine, can play a key role in treating Fragile X-related behavior difficulties. But the key to a medicine working is producing sure that it is really swallowed.
No matter how strong the powers of persuasion, convincing a child to take a medication can be incredibly challenging. Add to that behavioral difficulties, lack of understanding and uncontrollable reactions and imagine the stress and anxiety a child with Fragile X experiences throughout medicine time. Adding a scientifically developed flavoring designed specifically for medications to combat the unpleasant taste and smell of medications can make medicine time a lot a lot more pleasant and far more bearable. The FLAVORx system uses traditional flavors such as Grape, Cherry and Watermelon, as well as distinctive flavors such as Orange Cream, Butterscotch and Pina Colada to make certain that patients of all tastes and preferences are able to have a medication in a flavor of their selection. Practically all liquid medications prescribed for Fragile X can be flavored successfully, and tablet and capsule medications can be converted to suspension and quickly flavored. To date, FLAVORx has flavored over 40 million prescriptions without any incidence of allergy, adverse reaction or changes in efficacy. Safe for all children, FLAVORx flavors are FDA-approved, non-allergenic, sugar-free, sodium no cost, phosphate free, alcohol-totally free, dye-free of charge and incredibly concentrated so even a large bottle of medication only requires a minuscule amount of flavoring and does not disturb the dosage.
As a parent of a child with cerebral palsy himself, FLAVORx President and CEO Kenny Kramm understands firsthand the significance of producing medicine palatable, not only for improving health, but also for improving good quality of life. Kramm notes, “The true reward is understanding that there is some thing we can do to make these children’s lives just a small less difficult. There’s no reason why medicine ought to add a lot more trauma to the life of a child who is already scared and not feeling well.”
Aside from pharmacotherapy, treatment of Fragile X is also concentrated on special education, speech and language therapy, and behavioral analysis.
Fragile X is an “X-linked” disease located on the X chromosome and passed via inheritance. 1 in 250 ladies and 1 in 800 men carry the fragile X mutation, meaning that every single child born to a female carrier has a 50% chance of receiving the mutation, and a male carrier passes the mutation on to all his daughters. Several researchers view the discovery of the FMR1 gene and the study of Fragile X as a gateway to understanding other disorders related to brain development and function such as autism, hyperactivity and mental retardation. The FMR1 gene is also linked to Fragile X-associated tremor ataxia syndrome (FXTAS), which affects balance, tremor and memory in males, and Fragile X-related premature ovarian failure (POF), which can lead to infertility and early menopause in females.
For far more information, please contact Teresa Chen at 800.884.5771, extension 234.
# # #
Attachments
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Much more Treatment For Fragile X Syndrome Press Releases
No comments:
Post a Comment